Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Rampotas A., Carter-Brzezinski L., Somervaille TCP., Forryan J., Panitsas F., Harrison C., Witherall R., Innes AJ., Wallis L., Butt NM., Psaila B., Mead AJ., Carter M., Godfrey AL., Laing H., Garg M., Francis S., Ewing J., Teh CH., Cowen HB., Dyer P., McConville C., Wadelin F., Sahra A., McGregor A., Kulakov E., McLornan DP., Lambert J.
AbstractNonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.